Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Open DYAI dashboard ↗PDS Biotechnology Corporation Common Stock
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Open PDSB dashboard ↗